Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Factors associated with β-blocker initiation and discontinuation in a population-based cohort of seniors newly diagnosed with heart failure.

Girouard C, Grégoire JP, Poirier P, Moisan J.

Patient Prefer Adherence. 2016 Sep 15;10:1811-1821. eCollection 2016.

2.

Clinical factors associated with early readmission among acutely decompensated heart failure patients.

Pierre-Louis B, Rodriques S, Gorospe V, Guddati AK, Aronow WS, Ahn C, Wright M.

Arch Med Sci. 2016 Jun 1;12(3):538-45. doi: 10.5114/aoms.2016.59927. Epub 2016 May 18.

3.

Antihypertensive Medications and the Prevalence of Hyperkalemia in a Large Health System.

Chang AR, Sang Y, Leddy J, Yahya T, Kirchner HL, Inker LA, Matsushita K, Ballew SH, Coresh J, Grams ME.

Hypertension. 2016 Jun;67(6):1181-8. doi: 10.1161/HYPERTENSIONAHA.116.07363. Epub 2016 Apr 11.

5.

Age and sex differences in long-term outcomes following implantable cardioverter-defibrillator placement in contemporary clinical practice: findings from the Cardiovascular Research Network.

Masoudi FA, Go AS, Magid DJ, Cassidy-Bushrow AE, Gurwitz JH, Liu TI, Reynolds K, Smith DH, Reifler LM, Glenn KA, Fiocchi F, Goldberg R, Gupta N, Peterson PN, Schuger C, Vidaillet H, Hammill SC, Greenlee RT.

J Am Heart Assoc. 2015 Jun 2;4(6):e002005. doi: 10.1161/JAHA.115.002005.

6.

Hospital readmissions reduction program.

McIlvennan CK, Eapen ZJ, Allen LA.

Circulation. 2015 May 19;131(20):1796-803. doi: 10.1161/CIRCULATIONAHA.114.010270. No abstract available.

7.

Patterns of use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers among patients with acute myocardial infarction in China from 2001 to 2011: China PEACE-Retrospective AMI Study.

Liu J, Masoudi FA, Spertus JA, Wang Q, Murugiah K, Spatz ES, Li J, Li X, Ross JS, Krumholz HM, Jiang L; China PEACE Collaborative Group.

J Am Heart Assoc. 2015 Feb 23;4(2). pii: e001343. doi: 10.1161/JAHA.114.001343.

8.

SUrvey of Guideline Adherence for Treatment of Systolic Heart Failure in Real World (SUGAR): a multi-center, retrospective, observational study.

Yoo BS, Oh J, Hong BK, Shin DH, Bae JH, Yang DH, Shim WJ, Kim HS, Kim SH, Choi JO, Chun WJ, Go CW, Kang HJ, Baek SH, Cho JH, Hong SK, Shin JH, Oh SK, Pyun WB, Kwan J, Hong YJ, Jeong JO, Kang SM, Choi DJ; SUGAR Study.

PLoS One. 2014 Jan 27;9(1):e86596. doi: 10.1371/journal.pone.0086596. eCollection 2014.

9.

National trends in heart failure hospitalization after acute myocardial infarction for Medicare beneficiaries: 1998-2010.

Chen J, Hsieh AF, Dharmarajan K, Masoudi FA, Krumholz HM.

Circulation. 2013 Dec 17;128(24):2577-84. doi: 10.1161/CIRCULATIONAHA.113.003668. Epub 2013 Nov 4.

10.

Potentially inappropriate prescribing in institutionalised older patients in Spain: the STOPP-START criteria compared with the Beers criteria.

Ubeda A, Ferrándiz L, Maicas N, Gomez C, Bonet M, Peris JE.

Pharm Pract (Granada). 2012 Apr;10(2):83-91. Epub 2012 Jun 30.

11.

Comparative effectiveness research in heart failure therapies: women, elderly patients, and patients with kidney disease.

Shah RU, Chang TI, Fonarow GC.

Heart Fail Clin. 2013 Jan;9(1):79-92. doi: 10.1016/j.hfc.2012.09.003. Epub 2012 Oct 16. Review. No abstract available.

12.

Incremental Reduction in Risk of Death Associated With Use of Guideline-Recommended Therapies in Patients With Heart Failure: A Nested Case-Control Analysis of IMPROVE HF.

Fonarow GC, Albert NM, Curtis AB, Gheorghiade M, Liu Y, Mehra MR, O'Connor CM, Reynolds D, Walsh MN, Yancy CW.

J Am Heart Assoc. 2012 Feb;1(1):16-26. doi: 10.1161/JAHA.111.000018. Epub 2012 Feb 20.

13.

The evolving landscape of quality measurement for heart failure.

Fitzgerald AA, Allen LA, Masoudi FA.

Ann N Y Acad Sci. 2012 Apr;1254:131-9. doi: 10.1111/j.1749-6632.2012.06483.x. Review.

14.

Age and receipt of guideline-recommended medications for heart failure: a nationwide study of veterans.

Steinman MA, Harlow JB, Massie BM, Kaboli PJ, Fung KZ, Heidenreich PA.

J Gen Intern Med. 2011 Oct;26(10):1152-9. doi: 10.1007/s11606-011-1745-2. Epub 2011 May 21.

15.

Use of guideline-recommended therapies for heart failure in the Medicare population.

DiMartino LD, Shea AM, Hernandez AF, Curtis LH.

Clin Cardiol. 2010 Jul;33(7):400-5. doi: 10.1002/clc.20760.

16.

The effects of heart failure on renal function.

Udani SM, Koyner JL.

Cardiol Clin. 2010 Aug;28(3):453-65. doi: 10.1016/j.ccl.2010.04.004. Review.

17.

Epidemiology of chronic kidney disease in heart failure.

Ahmed A, Campbell RC.

Heart Fail Clin. 2008 Oct;4(4):387-99. doi: 10.1016/j.hfc.2008.03.008.

18.

The contribution of observational studies to the knowledge of drug effectiveness in heart failure.

Dobre D, van Veldhuisen DJ, DeJongste MJ, van Sonderen E, Klungel OH, Sanderman R, Ranchor AV, Haaijer-Ruskamp FM.

Br J Clin Pharmacol. 2007 Oct;64(4):406-14. Epub 2007 Aug 31. Review.

19.

Supplemental Content

Support Center